NCT07900867
This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Study description shortened, about 11 words
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 24
Timeframe: Baseline to Week 24
Secondary (6)
CLASI-70
CLASI-50
CLASI ≥7
CLA-IGA-R erythema
CLA-IGA-R OMC
Show 1 moreShow less
SLEDAI-2K
Arms and interventions
Group AExperimental
626 Dose A subcutaneous (SC) injection
Group BExperimental
626 Dose B subcutaneous (SC) injection
Group CExperimental
626 Dose C subcutaneous (SC) injection
Drugs: Placebo
Sites
2 sites in 1 country